Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis

Published:2018-05 Issue:5 Volume:29 Page:1329-1330
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Liu C.,Wang L.,Zhuang J.,Liu L.,Zhou C.,Feng F.,Sun C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdy067/24523832/mdy067.pdf

Reference5 articles.

1. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis;Ibrahim;Ann Oncol,2015

2. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy;Lipton;Clin Cancer Res,2008

3. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases;Lipton;JCO,2007

4. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates;Fizazi;JCO,2009

5. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure;Body;J Bone Miner Res,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Bioinformatics Analysis Reveals That miR-524-5p/MEF2C Regulates Bone Metastasis in Prostate Cancer and Breast Cancer;Computational and Mathematical Methods in Medicine;2022-09-10